Cathie Wood’s ARK Genomic Revolution ETF (ARKG) has invested $15.3 million in Ionis Pharmaceuticals (IONS), even as its stock has dropped nearly 37% following a disappointing late-stage trial result for a heart disease treatment. Despite this setback, Wood’s strategy suggests she believes in the company’s long-term prospects.
Ionis is pivoting to commercializing its own drugs, such as Tryngolza, which recently expanded its market potential after FDA approval for severe hypertriglyceridemia. Although recent trial failures may impact short-term profitability, the company aims for substantial revenue growth, with Wall Street projecting Tryngolza’s sales could peak at $3 billion. However, the transition to a commercial-stage biotech poses risks, particularly if future drug readouts do not meet expectations. Investors should exercise caution given the company’s potential volatility and current unprofitability.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.fool.com/investing/2026/07/18/cathie-wood-just-bet-big-on-this-biotech-stock/
